Sachiko Kawana

Sendai, 9810914, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Successful application of whole-liver irradiation in a patient with small cell lung cancer with diffuse liver metastasis: a case report.

Successful application of whole-liver irradiation in a patient with small cell lung cancer with diffuse liver metastasis: a case report.

Journal: Journal of medical case reports

Published: November 28, 2025

Immune checkpoint inhibitor rechallenge in advanced NSCLC: prognostic value of the neutrophil-to-lymphocyte ratio.

Immune checkpoint inhibitor rechallenge in advanced NSCLC: prognostic value of the neutrophil-to-lymphocyte ratio.

Journal: Translational lung cancer research

Published: September 25, 2025

A case of lower respiratory tract infection caused by Pandoraea sputorum in a human T-lymphotropic virus type 1 carrier.

A case of lower respiratory tract infection caused by Pandoraea sputorum in a human T-lymphotropic virus type 1 carrier.

Journal: IDCases

Published: June 16, 2025

Real-world outcomes and association between immune-related adverse events and therapeutic efficacy of nivolumab plus ipilimumab in elderly patients (≥75 years) with advanced non-small cell lung cancer.

Real-world outcomes and association between immune-related adverse events and therapeutic efficacy of nivolumab plus ipilimumab in elderly patients (≥75 years) with advanced non-small cell lung cancer.

Journal: Translational lung cancer research

Published: May 31, 2025

Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia.

Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: July 11, 2024

Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial.

Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: July 07, 2024

Efficacy of paclitaxel-carboplatin with bevacizumab as a late-line therapy for patients with advanced nonsquamous non-small cell lung cancer: A platinum rechallenge.

Efficacy of paclitaxel-carboplatin with bevacizumab as a late-line therapy for patients with advanced nonsquamous non-small cell lung cancer: A platinum rechallenge.

Journal: Thoracic cancer

Published: June 08, 2023

Gene expression signatures as candidate biomarkers of response to PD-1 blockade in non-small cell lung cancers.

Gene expression signatures as candidate biomarkers of response to PD-1 blockade in non-small cell lung cancers.

Journal: PloS one

Published: June 17, 2021

Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer.

Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer.

Journal: Cancer medicine

Published: February 03, 2021

Suppression of tumor immune microenvironment via microRNA-1 after epidermal growth factor receptor-tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma.

Suppression of tumor immune microenvironment via microRNA-1 after epidermal growth factor receptor-tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma.

Journal: Cancer medicine

Published: October 07, 2020

Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer.

Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer.

Journal: The oncologist

Published: July 22, 2019

Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab.

Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab.

Journal: JMA journal

Published: January 15, 2019

Showing 1-12 of 16

Last Updated: 09/26/2026